“Those who contributed to bedaquiline’s development should have a say in how the drug is priced. We’re calling on J&J to price bedaquiline at no more than $1 per day so that it can be made available to all people with drug-resistant TB. We will not back down until the price of bedaquiline is brought down,” said Sharonann Lynch, HIV & TB Policy Advisor for MSF’s Access Campaign.
Bedaquiline was developed with considerable taxpayer, non-profit and philanthropic support. Much of the critical work to inform the use of the drug and demonstrate its therapeutic value was conducted by the TB research community, health ministries, and treatment providers including MSF, and was financed by taxpayers and other donors. Despite this joint research and development effort by the global TB community, J&J alone owns the patent on the drug in many countries and has sole rights to determine in which countries the drug will be sold. Moreover, J&J also benefited from a significant financial windfall as it obtained a Priority Review Voucher from the US Food and Drug Administration (USFDA), that can be used to get accelerated marketing approval for another of its drugs.
If priced at $1 per day, the cost of bedaquiline would be $600 per person for the 20 months of treatment that many DR-TB patients require. In comparison, the lowest price J&J charges today for 20 months of bedaquiline is nearly double this at $1,200 ($2 per day) in countries eligible to purchase through the Global Drug Facility (GDF), a TB drug and diagnostic procurement mechanism, operating out of a UN agency. Meanwhile J&J charges other countries that are not eligible much more. This high price affects the scale-up of the drug in many countries struggling with DR-TB epidemics, considering that bedaquiline is just one of multiple drugs required in treatment regimens.
“Bedaquiline saved my life. I was experiencing a lot of side effects during my previous treatment which included drugs that need to be injected,” said Noludwe Mabandlela, who was treated for multidrug-resistant tuberculosis (MDR-TB) in Khayelitsha, South Africa and was cured in early 2019. “After switching to bedaquiline, my health improved much faster. I wouldn't wish anyone to go through what I experienced. Pharmaceutical corporations like J&J should stop inflating the price of the drug that offers a lifeline to people affected with drug-resistant forms of tuberculosis.”
Bedaquiline is one of only three new TB drugs to be developed in over half a century (the others are delamanid and pretomanid). The previously recommended DR-TB treatment regimens used by most countries required people to take as many as 20 pills a day for up to two years and endure painful daily injections and severe side effects ranging from psychosis and persistent nausea to deafness. These suboptimal treatments only cured 55% of people with multidrug-resistant tuberculosis (MDR-TB) and just 34% of people with extensively drug-resistant tuberculosis (XDR-TB).
Based on data generated by the TB community showing improved treatment outcomes in people who received bedaquiline, the World Health Organization in 2018 recommended bedaquiline be used as a core part of an all-oral treatment regimen, replacing the injected drugs. Increased use of bedaquiline has already shown benefits, even among people more likely to have poorer treatment outcomes, including people living with HIV, and people with pre-XDR-TB and XDR-TB. For example, in Belarus, among 244 people who were treated with bedaquiline – 96% of whom had either pre-XDR-TB or XDR-TB – the treatment success rate increased to 87%.
“We have seen so many patients go deaf, lose their jobs or lose their lives because they had no option other than the excruciating TB drugs that had to be injected,” said Pilar Ustero, Medical Advisor for MSF’s Access Campaign. “Now, bedaquiline is proving to be a gamechanger, giving those people with DR-TB who can access it a better chance to be cured, without the toxic side effects. We need this drug to be affordable for everyone who needs it, everywhere.”
Since the WHO recommended the use of bedaquiline a year ago as a core drug for the treatment of MDR-TB, less than 12,000 people were treated with a regimen including bedaquiline according to national TB programmes. This is a paltry figure considering that an estimated 80% of the 558,000 people who develop DR-TB annually (Global TB report 2018) should be treated with this drug. Rapid rollout of better-tolerated treatment containing bedaquiline will happen only if J&J makes it widely available in an affordable way, including by allowing other TB drug manufacturers to make generic versions.
NOTES TO EDITOR
MSF launch campaign outside J&J offices
As part of MSF’s campaign to urge J&J to drop the price, MSF will be joined by TB activists and civil society in protests outside of J&J offices in the US, South Africa, Brazil, Belgium, Ukraine and Spain on Thursday (10 October), demanding the corporation make the drug available for people with drug-resistant TB (DR-TB) for no more than a dollar a day.
MSF’s TB work
MSF is the largest non-governmental provider of TB treatment worldwide and has been involved in TB care for 30 years, often working alongside national health authorities to treat people in a wide variety of settings, including chronic conflict zones, urban slums, prisons, refugee camps, and rural areas. As of September 2018, across MSF projects in 14 countries, more than 2,000 people have been treated with the newer drugs, including 633 with delamanid—the only other new TB drug developed in more than 40 years—1,530 with bedaquiline, and 227 with a combination of both medicines.
MSF is also working to overcome patent barriers to this drug and to ensure the entry of multiple producers as a more long-term solution for access to affordable bedaquiline. In February 2019, MSF supported a patent challenge filed by two DR-TB survivors against J&J’s patent application in India. MSF is also urging the Indian government to override the patent and encourage its TB drug manufacturers to supply bedaquiline to its TB programme by issuing a ‘compulsory license’, considering that DR-TB is a public health emergency. This can be an effective way of eventually overcoming patent barriers to access critical health products, and other countries could follow suit and use the high price as grounds to also issue compulsory licenses.
 Under the neglected disease priority review voucher (PRV) program, when the US FDA approves an eligible neglected disease product—a medicine or vaccine—the developer is awarded a PRV. This voucher can then be used to accelerate the FDA review of any of the developer’s drugs or vaccines. Alternatively, the developer can choose to sell their voucher to another entity, as has been done previously for as much as US$350 million.
 Researchers from the University of Liverpool have calculated that bedaquiline could be produced and sold at a profit for much less – as little as 25 cents per day if at least 108,000 treatment courses were sold per year.